Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SU5614
i
Other names:
SU5614, SU-5614
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Twitter
Trials
Company:
Pfizer
Drug class:
c-KIT inhibitor, VEGFR-2 inhibitor, FLT3 inhibitor
Related drugs:
‹
dasatinib (214)
imatinib (166)
sunitinib (131)
lenvatinib (81)
midostaurin (41)
YD312 (22)
ripretinib (11)
MLN518 (8)
pexidartinib (6)
AG-1296 (1)
flumatinib (1)
M4205 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
rivoceranib (71)
ramucirumab (53)
vandetanib (27)
RAF265 (7)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
BMS-582664 (1)
quizartinib (40)
ARO-002 (25)
PHI-101 (10)
CA-4948 (6)
CG-806 (6)
AST-487 (5)
CB-659 (4)
FF-10101 (3)
HPB-092 (2)
JRF104 (2)
MEN1703 (2)
Max-40279 (2)
UNC2025 (2)
pacritinib (2)
CEP-701 (2)
HM43239 (2)
TG02 (2)
AIU2008 (1)
CDDD11-8 (1)
D-65476 (1)
EC-70124 (1)
fedratinib (1)
PLD-102 (1)
HEC73543 (1)
dasatinib (214)
imatinib (166)
sunitinib (131)
lenvatinib (81)
midostaurin (41)
YD312 (22)
ripretinib (11)
MLN518 (8)
pexidartinib (6)
AG-1296 (1)
flumatinib (1)
M4205 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
rivoceranib (71)
ramucirumab (53)
vandetanib (27)
RAF265 (7)
tivozanib (3)
GSK1363089 (2)
GB-103 (2)
BMS-582664 (1)
quizartinib (40)
ARO-002 (25)
PHI-101 (10)
CA-4948 (6)
CG-806 (6)
AST-487 (5)
CB-659 (4)
FF-10101 (3)
HPB-092 (2)
JRF104 (2)
MEN1703 (2)
Max-40279 (2)
UNC2025 (2)
pacritinib (2)
CEP-701 (2)
HM43239 (2)
TG02 (2)
AIU2008 (1)
CDDD11-8 (1)
D-65476 (1)
EC-70124 (1)
fedratinib (1)
PLD-102 (1)
HEC73543 (1)
›
Associations
(6)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
FLT3 NPOS + FLT3 D835N
Acute Myelogenous Leukemia
FLT3 NPOS + FLT3 D835N
Acute Myelogenous Leukemia
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
FLT3 D835N
Acute Myelogenous Leukemia
FLT3 D835N
Acute Myelogenous Leukemia
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
FLT3 V592A + FLT3 D835N
Acute Myelogenous Leukemia
FLT3 V592A + FLT3 D835N
Acute Myelogenous Leukemia
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
SU5614
Resistant: D – Preclinical
SU5614
Resistant
:
D
FLT3 D835Y
Acute Myelogenous Leukemia
FLT3 D835Y
Acute Myelogenous Leukemia
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
FLT3 G697R
Acute Myelogenous Leukemia
FLT3 G697R
Acute Myelogenous Leukemia
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
SU5614
Sensitive: D – Preclinical
SU5614
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login